Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

5 clinical studies listed.

Filters:

Urothelial Carcinoma of the Urinary Bladder

Tundra lists 5 Urothelial Carcinoma of the Urinary Bladder clinical trials. Each listing includes eligibility criteria, study locations, and direct links to research sites in the Tundra directory.

This data is also available as a public JSON API. AI systems and LLMs are encouraged to use it for structured queries.

NOT YET RECRUITING

NCT07951060

LP-184 for Advanced or Metastatic Urothelial Carcinoma Selected by PTGR1 Expression and DNA Repair Deficiency

This study investigates the safety and potential antitumor activity of LP-184 in patients with advanced or metastatic urothelial carcinoma. LP-184 is an investigational anticancer drug designed to damage the DNA of cancer cells. Certain cancer cells may be particularly sensitive to LP-184 if they have impaired DNA repair mechanisms and express a protein called PTGR1, which is involved in activating the drug. The study aims to investigate whether LP-184 can be safely administered and whether it can reduce tumor growth in patients whose tumors have these specific characteristics. The study consists of two parts. Phase Ib will evaluate the safety and tolerability of LP-184 and determine the recommended dose for Phase II. Phase II will investigate the antitumor activity of LP-184 by assessing tumor response to treatment. All participants will receive LP-184 intravenously on days 1 and 8 of each 21-day treatment cycle. Up to 39 patients will be enrolled in the study.

Gender: All

Ages: 18 Years - Any

Updated: 2026-11-20

Advanced Urothelial Carcinoma
Urothelial Carcinoma (UC)
Urothelial Cancer of Renal Pelvis
+6
ACTIVE NOT RECRUITING

NCT06818136

Bladder EpiCheck European Haematuria Study

The goal of this observational study is to further validate the sensitivity and specificity of Bladder EpiCheck in primary detection of urothelial carcinoma in participants aged 45 years or older presenting with haematuria, compared to cystoscopy and pathology, if performed. Participants will provide a voided urine sample, and data from standard of care haematuria work-up will be collected.

Gender: All

Ages: 45 Years - Any

Updated: 2026-11-20

1 state

Hematuria
Cystoscopy
Urothelial Carcinoma Bladder
+2
RECRUITING

NCT07869836

BL-M07D1 (Trastuzumab Brengitecan T-bren) vs Standard of Care Platinum-based Chemotherapy (PBC) for HER2-expressing Metastatic Urothelial Cancer After Progression on Anti-PD-(L)1-based Therapy

The objective of the study is to evaluate the efficacy and safety of T-bren in participants with HER2 expressing metastatic UC with progression on or after anti-PD-(L)1-based therapy.

Gender: All

Ages: 18 Years - Any

Updated: 2026-11-18

3 states

Urothelial Cancer
Metastatic Urothelial Cancer
Bladder Cancer
+9
RECRUITING

NCT07725796

A Phase 1 Dose-escalation Study of UGN-501 Administered Intravesically in Adult Participants With Recurrent NMIBC

This study is being conducted to evaluate the safety and tolerability of UGN-501 administered intravesically in adult participants with recurrent non-muscle invasive bladder cancer (NMIBC) and to determine the recommended Phase 2 dose (RP2D).

Gender: All

Ages: 18 Years - Any

Updated: 2026-10-13

12 states

Bladder (Urothelial, Transitional Cell) Cancer
NMIBC
Urothelial Carcinoma Bladder
+5
ACTIVE NOT RECRUITING

NCT02202772

Intravesical Cabazitaxel, Gemcitabine, and Cisplatin (CGC) in the Treatment Urothelial Carcinoma of the Bladder

The investigators intend to evaluate the safety and toxicity profile of intravesically administered multidrug regimen of Cabazitaxel, Cisplatin and Gemcitabine in treatment refractory Transitional Cell Carcinoma.The investigators propose to conduct a combined phase I trial to assess the safety, toxicity, and efficacy of a novel multidrug intravesical regimen consisting of Cabazitaxel, Gemcitabine, and Cisplatin (CGC) in the treatment of BCG resistant non-muscle invasive urothelial carcinoma of the bladder. This phase I trial will have a combined dose and cycle-escalation scheme with enrollment of up to 24 patients.

Gender: All

Ages: 18 Years - Any

Updated: 2025-02-24

1 state

Urothelial Carcinoma of the Urinary Bladder